We are live on ! Find out more
VRDN icon

Viridian Therapeutics

165 hedge funds and large institutions have $1.98B invested in Viridian Therapeutics in 2024 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 66 increasing their positions, 41 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

900% more funds holding in top 10

Funds holding in top 10: 110 (+9)

175% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 16

118% more capital invested

Capital invested by funds: $906M → $1.98B (+$1.07B)

61% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 41

20% more funds holding

Funds holding: 138165 (+27)

4.75% more ownership

Funds ownership: 109.13%113.88% (+4.8%)

8% more call options, than puts

Call options by funds: $13.9M | Put options by funds: $12.9M

Holders
165
Holders Change
+27
Holders Change %
+19.57%
% of All Funds
2.37%
Holding in Top 10
10
Holding in Top 10 Change
+9
Holding in Top 10 Change %
+900%
% of All Funds
0.14%
New
44
Increased
66
Reduced
41
Closed
16
Calls
$13.9M
Puts
$12.9M
Net Calls
+$1.01M
Net Calls Change
+$3.94M
Name Holding Trade Value Shares
Change
Change in
Stake
Teacher Retirement System of Texas
126
Teacher Retirement System of Texas
Texas
$318K +$59.9K +3,663 +35%
ASRS
127
Arizona State Retirement System
Arizona
$316K +$11.6K +710 +5%
LJAC
128
L.J. Altfest & Co
New York
$307K +$221K +13,512 New
BCM
129
Bayesian Capital Management
New York
$293K -$258K -15,782 -55%
State Board of Administration of Florida Retirement System
130
State Board of Administration of Florida Retirement System
Florida
$275K
ProShare Advisors
131
ProShare Advisors
Maryland
$269K +$193K +11,823 New
ACM
132
ADAR1 Capital Management
Texas
$209K +$19.7K +1,206 +15%
Connor, Clark & Lunn Investment Management (CC&L)
133
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$208K +$149K +9,130 New
A
134
AJOVista
Massachusetts
$201K +$144K +8,817 New
VEA
135
Virtus ETF Advisers
New York
$160K +$2.08K +127 +2%
PAS
136
Point72 Asia (Singapore)
Singapore
$149K +$107K +6,543 New
Royal Bank of Canada
137
Royal Bank of Canada
Ontario, Canada
$146K +$3.86K +236 +4%
AIP
138
Ameritas Investment Partners
Nebraska
$139K
ACM
139
Aster Capital Management
United Arab Emirates
$108K +$77.8K +4,756 New
TRCT
140
Tower Research Capital (TRC)
New York
$84.1K -$99.7K -6,097 -62%
CFM
141
Catalyst Funds Management
Australia
$43.2K -$50.7K -3,100 -62%
AB
142
Amalgamated Bank
New York
$38K
A
143
AlphaQuest
New York
$29K -$78.1K -4,780 -79%
Nisa Investment Advisors
144
Nisa Investment Advisors
Missouri
$23.8K -$1.37K -84 -7%
S
145
SignatureFD
Georgia
$22.8K +$16.3K +1,000 New
Simplex Trading
146
Simplex Trading
Illinois
$20K +$14.9K +911 New
Osaic Holdings
147
Osaic Holdings
Arizona
$14K -$1.86K -114 -16%
GI
148
GAMMA Investing
California
$4.25K +$2.88K +176 +1,600%
Carson Wealth (CWM LLC)
149
Carson Wealth (CWM LLC)
Nebraska
$3K +$409 +25 +27%
CA
150
Clearstead Advisors
Ohio
$2.87K

VRDN Hedge Fund Activity: Q3 2024 in Review

165 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q3 2024, worth a combined $1.98B — up 118% from $906M a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new VRDN positions and 16 closed out — a net gain of 28 holders — while 66 added to existing stakes and 41 trimmed.

The largest buyer was Driehaus Capital Management, opening a new position worth an estimated $32.6M. The largest seller was Maverick Capital, cutting an estimated $21.4M.

  • 165 institutional investors held Viridian Therapeutics (VRDN) as of Q3 2024, up from 138 in Q2 2024.
  • Funds reported $1.98B of Viridian Therapeutics stock for Q3 2024, up 118% quarter-over-quarter.
  • 44 funds opened new Viridian Therapeutics positions in Q3 2024 and 16 closed out, a net change of +28 holders.
  • The largest Viridian Therapeutics buyer in Q3 2024 was Driehaus Capital Management, an estimated $32.6M added.
  • The largest Viridian Therapeutics seller in Q3 2024 was Maverick Capital, an estimated $21.4M sold.

Based on aggregated 13F filings for Q3 2024.